ClearPoint Neuro Inc vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? ClearPoint Neuro Inc trades at $15.2 (market cap $454.21M), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $430.94 (market cap $1.93T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 4249.1× ClearPoint Neuro Inc's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.9% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | TSM | |
|---|---|---|
Market Cap | $454.21M | $1.93T |
Sector | Health | Technology |
52-Week High | $29.60 | $477.57 |
52-Week Low | $8.66 | $227.33 |
Enterprise Value | $488.79M | $1.85T |
Dividend Yield | — | 0.9% |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.
The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.
Taiwan Semiconductor Manufacturing (TSM) trades at $432.11, up 3.26% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. Revenue growth is robust, with July 2026 sales up 44.7% year-over-year (Bloomberg, 2026-08-10), driven by AI demand. The stock is supported by high profitability margins and a consensus analyst price target of $545.67, indicating significant upside potential.
The outlook remains positive given accelerating AI-driven revenue and expansion investments, but risks include geopolitical tensions in Taiwan and competitive pressures. Valuation multiples are elevated, with a P/E of 31.86, requiring sustained growth to justify current levels. Institutional sentiment is strongly bullish, with 72% of analysts rating the stock a buy.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →